Dextran

Polydex Pharmaceuticals Issues First Quarter Financial Results

Retrieved on: 
Wednesday, June 15, 2022
Management, African swine fever virus, CEO, Company, Usher, Research, Growth, Marketing, Dextran, COVID, Risk, Disclosure

Management believes that continued prudent cash and resource management is key to maintaining growth throughout the year, and has set this as a company goal.

Key Points: 
  • Management believes that continued prudent cash and resource management is key to maintaining growth throughout the year, and has set this as a company goal.
  • The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com .
  • These statements are typically identified by use of words like may, could, might, expect, anticipate, believe, or similar words.
  • Other risk factors discussed in the Companys financial reports may also affect the actual results achieved by the Company.

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Health, Department of Finance and Administration, Achievement, Tax, Director, Phase 3, Leadership, Derivative, Joint, CEO, Biopharmaceutical, Technetium-99m, Arm, Technology, RA, National, Food, Insurance, Dextran, Information technology, Administration, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Program, Cardinal, LLC, Board, Travel, Massachusetts General Hospital, A1, Company, Clinical study report, Small business, Q&A, Board of directors, NYSE, Massachusetts, Small Business Innovation Research, Brothers in Arms 2: Global Front, Patient, FDA, Molecular mass, Biopsy, Total, Fine chemical, Management, Pharmaceutical industry

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2021.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2021.
  • Total net revenues for the third quarter of 2021 were $96,000, compared to $268,000 for the same period in 2020.
  • R&D expenses for the third quarter of 2021 were $1.0 million, compared to $1.4 million in the same period in 2020.
  • Navidea ended the third quarter of 2021 with $7.2 million in cash and cash equivalents.

Polydex Pharmaceuticals Issues First Quarter Financial Results

Retrieved on: 
Tuesday, June 15, 2021
Articles, Financial risk, Risk factor, Dextran, Lluís Companys, Risk, Academic disciplines, Economy

Additionally, he added, we have continued to investigate new markets for our powdered products and Native Dextran for industrial uses.

Key Points: 
  • Additionally, he added, we have continued to investigate new markets for our powdered products and Native Dextran for industrial uses.
  • We are actively pursuing these new markets and collaborations in an effort to maintain profitability in fiscal 2022.
  • The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com .
  • Other risk factors discussed in the Companys financial reports may also affect the actual results achieved by the Company.

Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference

Retrieved on: 
Monday, May 24, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Diarrhea, Inflammatory bowel disease, Dextran, Hepatitis, Colitis

Of the six presentations, two discussed data from studies of SZN-1326, a bi-specific full-length human antibody targeting Fzd5/8 and Lrp6 receptors in development for the treatment of inflammatory bowel disease (IBD).

Key Points: 
  • Of the six presentations, two discussed data from studies of SZN-1326, a bi-specific full-length human antibody targeting Fzd5/8 and Lrp6 receptors in development for the treatment of inflammatory bowel disease (IBD).
  • Four presentations discussed data from studies of SZN-043, a hepatocyte-targeted R-spondin mimetic for severe alcoholic hepatitis.
  • A replay of the oral presentation and copies of the ePosters will be posted in the Investors & Media section of Surrozens website when available.
  • As part of the study, mice were subjected to dextran sulfate sodium (DSS) and developed severe colitis.

Dextran Global Market Insights (2020 to 2025) - Analysis and Forecasts

Retrieved on: 
Tuesday, December 15, 2020
Dextran, Polysaccharides, Draft:Away From Home

DUBLIN, Dec. 15, 2020 /PRNewswire/ -- The "Dextran Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 15, 2020 /PRNewswire/ -- The "Dextran Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering.
  • This report describes the global market size of Dextran from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.
  • For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.
  • This report covers the following regions:

Global Dextran Market to 2025 - by Manufacturers, Regions, Technology and Product Type - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 8, 2020
Health, Pharmaceutical, Dextran, Polysaccharides, ASEAN, Compound annual growth rate, Articles, Academic disciplines

This report describes the global market size of Dextran from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.

Key Points: 
  • This report describes the global market size of Dextran from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.
  • For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.
  • The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
  • For the competitor segment, the report includes global key players of Dextran as well as some small players.

Intravenous (IV) Iron Drugs: The Global Market is Projected to Grow Tremendously During 2018-2022

Retrieved on: 
Thursday, November 15, 2018
RTT, Hematology, Medicine, Blood, Iron sucrose, Iron supplement, Iron deficiency, Anemia, Dextran, Iron-deficiency anemia, Anemia of chronic disease

2.3 Intravenous Iron Drugs Segmentation: An Overview

Key Points: 
  • 2.3 Intravenous Iron Drugs Segmentation: An Overview
    3.1 Global Iron Drugs Market: An Analysis
    3.2 Global Intravenous (IV) Iron Drugs Market: An Analysis
    3.2.2 Global IV Iron Drugs Market by Product (Injectafer/Ferinject, Venofer and Other Products)
    3.2.3 Global IV Iron Drugs Market by Type (Ferric Carboxymaltose, Sucrose, Dextran and Others)
    3.2.4 Global IV Iron Drugs Market by Region (The US, Europe and ROW)
    3.3 Global Intravenous (IV) Iron Drugs Market: Product Analysis
    3.4 Global Intravenous (IV) Iron Drugs Market: Type Analysis
    4.1 The US Intravenous (IV) Iron Drugs Market: An Analysis
    4.1.2 The US IV Iron Drugs Market by Products (Venofer, Injectafer and Other Products)
    4.1.3 The US IV Iron Drugs Market by Indication (Chronic Kidney Disease, Iron Deficiency Anemia, Inflammatory Bowel Disease, Oncology and Heart Failure)
    4.2 The US Intravenous (IV) Iron Drugs Market: Product Analysis
    4.2.2 The US Injectafer IV Iron Drugs Market by Indication (Iron Deficiency Anemia, Inflammatory Bowel Disease, Oncology, Chronic Kidney Disease, Heart Failure and Other)
    4.3 The US Intravenous (IV) Iron Drugs Market: Indication Analysis
    4.4 Europe Intravenous (IV) Iron Drugs Market: An Analysis